GDF15 and Huntington disease: In this study, we evaluated whether GDF-15 levels are modified during the first year of HD therapy since GDF-15 has recently been identified as a surrogate marker of inflammation [26], oxidative stress [27] and senescence [28] and is strongly associated with cardiovascular risk and mortality in HD patients [29].